Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Collagen alpha-1(I) chain (COL1A1) is a major structural component of type I collagen, the most abundant fibrillar collagen in the human body, primarily found in bones, skin, tendons, and other connective tissues. Type I collagen typically exists as a heterotrimer composed of two alpha-1 chains (encoded by COL1A1) and one alpha-2 chain (encoded by COL1A2). COL1A1 plays a fundamental role in maintaining tissue structural integrity, cell morphology, and extracellular matrix (ECM) homeostasis. In pathological states, aberrant upregulation of COL1A1 is a hallmark of various fibrotic diseases, including idiopathic pulmonary fibrosis, liver cirrhosis, and systemic sclerosis, where excessive collagen deposition leads to organ dysfunction. Additionally, COL1A1 is highly expressed in the tumor microenvironment of several cancers (such as ovarian, pancreatic, and colorectal cancers), where it promotes tumor cell proliferation, invasion, chemoresistance, and immune evasion. Conversely, loss-of-function mutations in the COL1A1 gene are associated with genetic disorders such as osteogenesis imperfecta and Ehlers-Danlos syndrome. Therapeutic strategies targeting COL1A1 include small molecules like halofuginone, which specifically inhibits COL1A1 gene expression and collagen synthesis, as well as broader anti-fibrotic agents like pirfenidone and nintedanib that suppress collagen production by modulating upstream TGF-beta and tyrosine kinase signaling pathways.
Inhibition of COL1A1 gene transcription and translation, suppression of TGF-beta/Smad signaling pathway to reduce collagen synthesis, disruption of extracellular matrix deposition and collagen fibril assembly, and inhibition of mTOR/p70S6K pathway to suppress collagen production
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Collagen alpha-1(I) chain (COL1A1).